The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
Official Title: A Phase 2, Multicenter, Open-label Study of BGJ398 in Patients With Recurrent Resectable or Unresectable Glioblastoma
Study ID: NCT01975701
Brief Summary: This is an open-label non-randomized, multicenter, phase II study of BGJ398 administered to adult patients with histologically confirmed GBM and/or other glioma subtypes with FGFR1-TACC1, FGFR3-TACC3 fusion and/or activating mutation in FGFR1, 2 or 3.
Detailed Description: Patients were enrolled in two groups. Group 1 enrolled patients who are not candidates for surgery. Group 2 was planned to enroll patients who are surgical candidates. Patients from both groups were evaluated for tumor response and progression by MRI every 8 weeks until disease progression or discontinuation from study using RANO criteria.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Novartis Investigative Site, Los Angeles, California, United States
University of California San Francisco Dept of Onc., San Francisco, California, United States
Novartis Investigative Site, Chicago, Illinois, United States
Novartis Investigative Site, Boston, Massachusetts, United States
Novartis Investigative Site, New York, New York, United States
Novartis Investigative Site, Columbus, Ohio, United States
Novartis Investigative Site, Dallas, Texas, United States
Novartis Investigative Site, Dallas, Texas, United States
Novartis Investigative Site, Houston, Texas, United States
Novartis Investigative Site, Melbourne, Victoria, Australia
Novartis Investigative Site, Leuven, , Belgium
University Medical Center Utrecht, Utrecht, The Netherlands, Netherlands
Novartis Investigative Site, Barcelona, Catalunya, Spain
Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Zürich, , Switzerland
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR